 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
Amarillo Biosciences (NASDAQ:AMAR) is an early stage bio-technology company engaged in developing biologics for the treatment of human and animal diseases. AMAR made an initial public offering of 2.3 million shares of stock in August. The company is currently focusing its research on human health indications for the use of low dose orally delivered natural interferon alpha. Particularly for the treatment of Sjogren's syndrome, oral musositis in cancer patients and hepatitis B and C. A large worldwide market exists for the low dose oral natural interferon as an inexpensive, non-toxic, efficacious treatment for disease. The company owns or licenses 11 United States patents relating to low dose oral natural interferon. AMAR is also testing oral interferon in cats with herpesvirus-1 infection, dogs with keratoconjunctivitis sicca and cattle with shipping fever or mastitis. The company has filed investigational new animal drug notices which are now in effect, for these and other indications, in animals. AMAR is rather closely held by the following: Hayashibara Biochemical Laboratories Inc. holds a 24.1 percent stake or 1,232,856 common shares. Hayashibara manufactures and supplies oral interferon alpha exclusively to AMAR for human applications outside Japan and animal applications worldwide. Mochida Pharmaceutical Co Ltd holds a 5.9 percent stake or 300,000 common shares. Mochida is a Japanese corporation in the business of developing and marketing ethical drugs, diagnostic reagents, skin care products and medical electronics and equipment. Joseph Cummins, a Texas investor holds a 13.6 percent stake or 696,804 common shares. Announcements are anticipated in the coming months regarding trial results of AMAR's products. | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2026 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |